Literature DB >> 15070606

Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients.

Joerg Wacker1, Benjamin Khan-Durani, Wolfgang Hartschuh.   

Abstract

BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a very rare, low-grade malignant tumor. Local recurrence is frequent after incomplete resection either because of false diagnosis or inadequate standard surgical excision. This study evaluated the clinical outcome of micrographic surgery with paraffin sectioning in the therapy of DFSP.
METHODS: Medical charts of 22 patients with histologically confirmed DFSP treated at our institution between 1987 and 2002 were reviewed.
RESULTS: For 13 patients with primary and 9 with recurrent disease, tumor-free excision margins could be achieved, and all patients remained free of local recurrence during a mean follow-up of 54 months.
CONCLUSIONS: The results of our study and a review of the literature confirm the successful and recurrence-free treatment of DFSP with micrographic surgery as the treatment of choice for this locally invasive tumor. Particularly in recurrent lesions, we recommend the use of paraffin sectioning and three-dimensional histological evaluation as an accurate additional tool for treatment optimization.

Entities:  

Mesh:

Year:  2004        PMID: 15070606     DOI: 10.1245/ASO.2004.06.014

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Dermatofibrosarcoma protuberans of penis: Case report and literature review.

Authors:  Hamid Raashid; Zaroo Inaam; Hafeez Aadil; M A Darzi; Ataf Rasool; Hamid Abdul; Afrozah Akhter
Journal:  Urol Ann       Date:  2014-07

2.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Authors:  Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

3.  Micrographic Surgery Allows Fascia Preservation in Dermatofibro-sarcoma Protuberans.

Authors:  Maximilian Gassenmaier; Erik Weber; Ulrike Leiter; Matthias Hahn; Stephan Forchhammer; Hans-Martin Häfner; Alexander Scheu; Claus Garbe; Saskia Schnabl
Journal:  Acta Derm Venereol       Date:  2021-09-28       Impact factor: 3.875

4.  Intracranial recurrence and distant metastasis of scalp dermatofibrosarcoma protuberans.

Authors:  Jurica Marakovic; Milorad Vilendecic; Tonko Marinovic; Smiljka Lambasa; Gordan Grahovac
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

Review 5.  Current treatment options in dermatofibrosarcoma protuberans.

Authors:  Doreen Lemm; L-O Mügge; T Mentzel; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

6.  Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.

Authors:  Piotr Rutkowski; Agnieszka Wozniak; Tomasz Switaj
Journal:  Sarcoma       Date:  2011-03-30

7.  Wide Local Excision for Dermatofibrosarcoma Protuberans: A Single-Center Series of 90 Patients.

Authors:  Byung Jun Kim; Hyeonwoo Kim; Ung Sik Jin; Kyung Won Minn; Hak Chang
Journal:  Biomed Res Int       Date:  2015-11-25       Impact factor: 3.411

Review 8.  The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans.

Authors:  Malumani Malan; Wu Xuejingzi; Song Ji Quan
Journal:  Pan Afr Med J       Date:  2019-08-13

9.  Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report.

Authors:  Francois G Kamar; Victor F Kairouz; Alain N Sabri
Journal:  Clin Sarcoma Res       Date:  2013-04-04

Review 10.  Dermatofibrosarcoma protuberans: from translocation to targeted therapy.

Authors:  Jonathan Noujaim; Khin Thway; Cyril Fisher; Robin L Jones
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.